Follow-The-Filings

Security

ARWR

Arrowhead Pharmaceuticals In · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

13 owners 1 new 1 exit max 0.1% (Renaissance Technologies LLC)

grid → activity →
owners 13
max % 0.1%
tracked value $1.4B
qoq N 1 A 4 R 6 E 1

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Renaissance Technologies LLC 2026 Q1 0.1% New 0.1% 1,036,495 $65M hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% Add +0.04 pp 1,183,838 $74M hist
Ray Dalio - Bridgewater Associates, LP 2026 Q1 0.0% Add +0.01 pp 95,552 $6M hist
Ken Fisher - Fisher Asset Management, LLC 2026 Q1 0.0% Reduce -0.01 pp 1,113,568 $70M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Reduce -0.01 pp 206,412 $13M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Reduce +0.01 pp 15,293,121 $1B hist
Norges Bank 2025 Q4 stale 0.0% Exit -0.01 pp 1,704,464 $113M hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Add 0.00 pp 179,573 $11M hist
Joel Greenblatt - Gotham Asset Management, LLC 2026 Q1 0.0% Reduce -0.01 pp 38,168 $2M hist
Farallon Capital Management LLC 2026 Q1 0.0% — 15,800 $991 hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% Add 0.00 pp 167,210 $10M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Reduce 0.00 pp 98,194 $6M hist
Natixis Advisors, LLC 2026 Q1 0.0% Reduce 0.00 pp 18,170 $1M hist
Israel Englander - Millennium Management LLC exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 45,018 $3M hist

13 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $240.74M $3.55M $829.45M
Gross profit — — —
Gross margin — — —
Net income -$205.28M -$599.49M -$1.63M
Net margin * -85.3% -16882.4% -0.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $419.52M $695.47M $950.64M
Total non-current assets * $346.03M $444.33M $434.66M
Total assets $765.55M $1.14B $1.39B
Total current liabilities $105.46M $103.17M $195.49M
Total non-current liabilities $372.93M $845.57M $686.39M
Total equity $271.34M $185.44M $466.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$153.89M -$462.85M $179.55M
Cash from investing -$96.16M -$420.07M -$129.29M
Cash from financing $253.05M $870.52M $74.01M
Net change in cash * $3.01M -$12.4M $124.26M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders